我院2006～2008年血管紧张素Ⅱ受体拮抗药应用分析

Utilization of Angiotensin Ⅱ Receptor Blockers in Our Hospital from 2006 to 2008

目的:评价我院血管紧张素Ⅱ受体拮抗药(ARB)的临床使用情况。方法:比较我院2006～2008年ARB与血管紧张素转换酶抑制剂(ACEI)、钙拮抗药的临床使用数据,包括用药频度(DDDs)与销售金额等。结果:ARB的销售金额和所占比例逐年增加;其DDDs均有所增长,以厄贝沙坦、替米沙坦增长速度最快,氯沙坦钾的DDDs连续3年最大。结论:ARB作为我院的主流降压药,越来越受到医师和患者欢迎,临床使用空间巨大。

OBJECTIVE： To evaluate the clinical utilization of angiotensin Ⅱ receptor blockers（ARBs） in our hospital. METHODS： The clinical utilization data such as the DDDs and consumption sum of ARBs, angiotensin- converting enzyme inhibitors（ACEIs） and calcium antagonists during 2006--2008 in our hospital were evaluated. RESULTS： Both the consumption sum and proportion of ARBs increased year by year, and the DDDs of ARBs increased as well. Irbesartan and telmisartan showed the most rapid increase and losartan potassium took the lead over the three years. CONCLUSION： As a mainstream type of antihypertensive drugs, ARBs get more and more popularity among doctors and patients, and the clinical application of which enjoy a great potential.